Clinical Trials Browser

Triple Negative Breast Neoplasms

Neurofibromatosis 1, Neurofibroma, Plexiform

Neurofibromatosis 1

Ependymoma, Glioma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

Lymphoma, Non-Hodgkin, Neuroblastoma, Central Nervous System Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Rectal Neoplasms

Carcinoma, Non-Small-Cell Lung, Neoplasms

Cystadenocarcinoma, Serous

Breast Neoplasms

Pancreatic Neoplasms

Differentiated Thyroid Cancer

Locally Advanced or Metastatic Solid Tumors

Carcinoma, Non-Small-Cell Lung

Uveal Melanoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Neoplasm Metastasis, Thyroid Diseases, Thyroid Neoplasms

Breast Neoplasms

Thyroid Cancer, Papillary, Thyroid Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

Solid Tumors

Biliary Tract Neoplasms

Bile Duct Neoplasms, Carcinoma, Hepatocellular

Adult Solid Neoplasm

Solid Tumours

Multiple Myeloma

Carcinoma, Hepatocellular

Clinical Trials

AMTEC IIT: Phase 2 Multiarm Study in TNBC

KOMET

SPRINKLE

SEL-TH-1601

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

MK-5618-001

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

DOC-MEK

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

MK-8353-014

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum

A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

Personalized Treatment Selection for Metastatic Breast Cancer

Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

ASTRA

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer

Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine

Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer

A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects

Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study

Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

Selumetinib in Cancers With BRAF Mutations

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV